Threshold Pharmaceuticals Inc. (NASDAQ:THLD) Given Consensus Recommendation of “Hold” by Brokerages
Threshold Pharmaceuticals Inc. (NASDAQ:THLD) has been given an average rating of “Hold” by the six analysts that are currently covering the stock. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.26.
Several research firms have recently issued reports on THLD. S&P Equity Research cut their price objective on shares of Threshold Pharmaceuticals from $0.67 to $0.52 in a report on Friday. William Blair restated an “outperform” rating on shares of Threshold Pharmaceuticals in a report on Monday.
Threshold Pharmaceuticals (NASDAQ:THLD) traded down 7.2627% during midday trading on Tuesday, reaching $0.5529. 1,657,826 shares of the company’s stock were exchanged. The firm has a market capitalization of $39.54 million, a price-to-earnings ratio of 0.9340 and a beta of 3.98. The firm’s 50 day moving average is $1.06 and its 200 day moving average is $0.62. Threshold Pharmaceuticals has a 52 week low of $0.21 and a 52 week high of $4.44.
Threshold Pharmaceuticals (NASDAQ:THLD) last announced its earnings results on Monday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.10). On average, equities analysts anticipate that Threshold Pharmaceuticals will post ($0.38) earnings per share for the current year.
A number of large investors have recently modified their holdings of the stock. Oxford Asset Management raised its stake in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of Threshold Pharmaceuticals during the second quarter worth approximately $152,000. Renaissance Technologies LLC raised its stake in shares of Threshold Pharmaceuticals by 55.5% in the first quarter. Renaissance Technologies LLC now owns 1,016,764 shares of the biotechnology company’s stock worth $468,000 after buying an additional 363,100 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Threshold Pharmaceuticals by 16.7% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,500,000 shares of the biotechnology company’s stock worth $1,610,000 after buying an additional 500,000 shares in the last quarter. Finally, Deerfield Management Co. purchased a new stake in shares of Threshold Pharmaceuticals during the second quarter worth approximately $1,641,000. Hedge funds and other institutional investors own 28.22% of the company’s stock.
About Threshold Pharmaceuticals
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.